Association of S100A8/A9 with lipid-rich necrotic core and treatment with biologic therapy in patients with psoriasis: results from an observational cohort study.
Alexander R Berg,Christin G Hong,Maryia Svirydava,Haiou Li,Philip M Parel,Elizabeth Florida,Ross O'Hagan,Carla J Pantoja,Sundus S Lateef,Paula Anzenberg,Charlotte L Harrington,Grace Ward,Wunan Zhou,Alexander V Sorokin,Marcus Y Chen,Heather L Teague,Andrew J Buckler,Martin P Playford,Joel M Gelfand,Nehal N Mehta,Alexander R. Berg,Christin G. Hong,Philip M. Parel,Ross O’Hagan,Carla J. Pantoja,Sundus S. Lateef,Charlotte L. Harrington,Alexander V. Sorokin,Marcus Y. Chen,Heather L. Teague,Andrew J. Buckler,Martin P. Playford,Joel M. Gelfand,Nehal N. Mehta
DOI: https://doi.org/10.1016/j.jid.2022.05.1085
IF: 7.59
2022-06-26
Journal of Investigative Dermatology
Abstract:Psoriasis is a systemic inflammatory disease with increased risk of atherosclerotic events and premature cardiovascular disease. S100A7, A8/A9, and A12 are protein complexes that are produced by activated neutrophils, monocytes, and keratinocytes in psoriasis. Lipid-rich necrotic core (LRNC) is a high-risk coronary plaque feature previously found to be associated with cardiovascular risk factors and psoriasis severity. LRNC can decrease with biologic therapy, but how this occurs remains unknown. We investigated the relationship between S100 proteins, LRNC, and biologic therapy in psoriasis. S100A8/A9 associated with LRNC in fully adjusted models (β = 0.27, P = 0.009, n=125 psoriasis patients with available coronary CT angiography scans, LRNC analyses, and serum S100A7, S100A8, S100A9, S100A12, and S100A8/A9 levels). At one year, in patients receiving biologic therapy (36 of 73 patients had 1-year CCTA scans available), a 79% reduction in S100A8/A9 levels (-172 (-291.7-26.4) vs -29.9 (-137.9- 50.5) P = 0.04) and a 0.6 mm reduction in average LRNC area (0.04 (-0.48-0.77) vs -0.56 (-1.8- 0.13); P = 0.02) were noted. These results highlight the potential role of S100A8/A9 in the development of high-risk coronary plaque in psoriasis.
dermatology